← 產業報告目錄

Preeclampsia Therapeutics Market Research Report by Drug Class (Antihypertensive Drugs, Anticonvulsants, Corticosteroids, Others), by Disease Severity (Mild, Severe), by Route of Administration (Oral, Intravenous (IV), Intramuscular (IM)), by Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies), by Region (North America, Europe, Asia Pacific, South America, Middle East & Africa) Forecast till 2035

出版商 Market Research Future產業別 Healthcare & Life Sciences出版日期 2026-05-02頁數 183報告編號 MRFRHC38133CR

授權報價

Single User Price$4,950 USD
Multi User Licence (up to 10 users)$5,950 USD
Enterprisewide Price (Global Site License)$7,250 USD
洽詢購買 申請 Sample

報告摘要

The global Preeclampsia Therapeutics Market was valued at USD 337.02 million in 2025 and is projected to reach USD 610.77 million by 2035. The market is expected to grow at a CAGR of 6.2% during the forecast period, driven by rising cases of hypertensive disorders during pregnancy and increasing awareness regarding maternal healthcare. Rising Prevalence of Maternal Risk Factors Driving Market Growth One of the leading factors that are causing a higher incidence of preeclampsia internationally is the rising rates of obesity, hypertension, diabetic conditions, and delayed childbirth among women. Since the condition is one of the main causes of both maternal and fatal deaths, the increasing number of cases is fuelling the search for and availability of efficacious therapies and preventative treatments. Segment Insights By Drug Class: • Antihypertensive Drugs: Widely prescribed for controlling pregnancy-related hypertension. • Anticonvulsants: Essential for preventing seizures in severe cases. • Corticosteroids: Support fatal lung development during premature deliveries. • Others: Include supportive therapies for symptom management. By Disease Severity: • Mild: Early-stage cases requiring continuous medical monitoring. • Severe: High-risk conditions demanding immediate therapeutic intervention. By Route of Administration: • Oral: Preferred for convenient long-term medication administration. • Intravenous (IV): Enables rapid drug delivery during emergencies. • Intramuscular (IM): Used for controlled therapeutic drug administration. By Distribution Channel: • Hospital Pharmacies: Major distribution channel for critical care treatments. • Retail Pharmacies: Improve accessibility of prescribed therapeutic medications. • Online Pharmacies: Expanding through growing digital healthcare adoption. Due to their remarkable healthcare facilities, robust maternal-care oriented legislations, and timely embracement of advanced treatment methodologies, North America and Europe have been at the forefront of the preeclampsia therapeutics market. On the other hand, maternal-health consciousness, hospital network expansion, and prenatal-care access improvement have been the prime factors for the rapid growth of Asia-Pacific, South America, and Middle East & Africa regions. Strong Portfolio Execution by GSK GSK reaffirmed its long-term growth prospects by delivering a strong 2025 performance at the beginning of this year, which has been publicly disclosed in the media. Specialty medicines, a high level of research & development, and product launches in the key therapeutic areas have been the major contributors to the company's strong momentum. All these areas reflect the disciplined portfolio execution and the innovation-led strategy. Emergence of Targeted Molecular Therapies At present, the recent market players from the preeclampsia therapeutics segment profit strategically from the ongoing change in clinical practice from symptom management to targeted molecular therapies. A few noteworthy examples of the newer class of medicines are those based on siRNA and can silence the expression of target genes such as sFlt-1 whose overproduction is one of the hallmarks of preeclampsia, thereby leading the forefront of precision medicine aiming at the root cause of the disease instead of merely offering symptomatic relief. Key Report Attributes • Market Size 2025: USD 337.02 Million • Market Size 2035: USD 610.77 Million • CAGR (2025-2035): 6.2% • Base Year: 2024 • Market Forecast Period: 2025-2035 Industry Segmentations Growth • By Drug Class: Antihypertensive Drugs - 5.7%, Anticonvulsants - 8.3%. • By Disease Severity: Mild - 5.6%, Severe - 6.6%. • By Route of Administration: Oral - 4.9%, Intravenous (IV) - 7.1%. • By Distribution Channel: Hospital pharmacies - 5.5%, Retail pharmacies - 7.3%.
目錄 Table of Contents
TABLE OF CONTENTS 1 EXECUTIVE SUMMARY ........................................... 18 2 MARKET INTRODUCTION ....................................... 20 2.1 DEFINITION ...................... 20 2.2 SCOPE OF THE STUDY ...... 20 2.3 RESEARCH OBJECTIVE ........... 20 2.4 MARKET STRUCTURE ........ 21 3 RESEARCH METHODOLOGY ................................. 22 3.1 OVERVIEW .......................... 22 3.2 DATA FLOW ........................ 24 3.2.1 DATA MINING PROCESS ...................................... 24 3.3 PURCHASED DATABASE: ........ 25 3.4 SECONDARY SOURCES: .......... 26 3.4.1 SECONDARY RESEARCH DATA FLOW: .................. 27 3.5 PRIMARY RESEARCH: ............ 28 3.5.1 PRIMARY RESEARCH DATA FLOW: ...................... 29 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED ......................... 30 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE ....... 30 3.6 APPROACHES FOR MARKET SIZE ESTIMATION: ........................ 31 3.6.1 REVENUE ANALYSIS APPROACH .......................... 31 3.7 DATA FORECASTING ............... 31 3.7.1 DATA FORECASTING TYPE ................................... 32 3.8 DATA MODELING .................. 33 3.8.1 MICROECONOMIC FACTOR ANALYSIS: ................. 33 3.8.2 DATA MODELING: ..... 34 3.9 TEAMS AND ANALYST CONTRIBUTION ................................... 36 4 MARKET DYNAMICS ............................................... 38 4.1 INTRODUCTION ..................... 38 4.2 DRIVERS ............................. 39 4.2.1 RISING PREVALENCE OF RISK FACTORS ............... 39 4.2.2 INCREASED INCIDENT CASES .............................. 39 4.2.3 HIGH USE OF ANTIHYPERTENSIVES & MAGNESIUM SULFATE .......................... 40 4.2.4 INCREASING AWARENESS OF PREECLAMPSIA...... 40 4.3 RESTRAINTS ........................ 42 4.3.1 LIMITED TARGETED THERAPIES ........................... 42 4.3.2 DRUG SAFETY RESTRICTIONS IN PREGNANCY ...... 43 4.3.3 HOSPITAL BASED TREATMENT DEPENDENCY ...... 44 4.4 OPPORTUNITIES ................... 45 4.4.1 DEVELOPMENT OF NEW THERAPIES .................... 45 4.4.2 EARLY SCREENING & PREVENTIVE THERAPY ........ 45 5 MARKET FACTOR ANALYSIS ................................. 46 5.1 REGULATORY ENVIRONMENT & COMPLIANCE .......................... 46 5.2 TECHNOLOGICAL TRENDS & INNOVATION ............................... 47 5.3 PATIENT DEMOGRAPHICS & DISEASE BURDENS ..................... 48 5.4 PRICING ANALYSIS & REIMBURSEMENT DYNAMICS ................ 48 5.4.1 NORTH AMERICA ..... 48 5.4.2 EUROPE ................... 48 5.4.3 ASIA PACIFIC ........... 49 5.4.4 REST OF THE WORLD ........................................... 49 5.4.5 REIMBURSEMENT DYNAMICS .............................. 49 5.5 MARKET ENTRY & EXIT BARRIERS .......................................... 50 5.5.1 BARRIERS TO ENTRY ........................................... 50 5.5.2 BARRIERS TO EXIT ............................................... 50 5.6 PARTNERSHIPS & COLLABORATIONS ...................................... 50 5.7 CONSUMER & HEALTHCARE PROVIDER PREFERENCES ............... 51 5.8 PESTLE ANALYSIS ............ 52 5.8.1 POLITICAL FACTORS ........................................... 52 5.8.2 ECONOMIC FACTORS .......................................... 52 5.8.3 SOCIAL FACTORS ..... 52 5.8.4 TECHNOLOGICAL FACTORS ................................. 53 5.8.5 LEGAL FACTORS ...... 53 5.8.6 ENVIRONMENTAL FACTORS ................................ 53 5.9 PORTER'S FIVE FORCES MODEL ........................................... 53 5.9.1 THREAT OF NEW ENTRANTS ................................ 54 5.9.2 BARGAINING POWER OF SUPPLIERS .................... 54 5.9.3 THREAT OF SUBSTITUTES ................................... 55 5.9.4 BARGAINING POWER OF BUYERS ......................... 55 5.9.5 INTENSITY OF RIVALRY ....................................... 55 5.10 PRODUCT PIPELINE ANALYSIS ............................................. 56 5.11 CASE STUDY ANALYSIS ......... 56 5.12 INVESTMENT & FUNDING SCENARIOS ................................... 57 5.13 POST-MARKET SURVEILLANCE & SAFETY DATA ........................ 57 5.14 DISEASE OVERVIEW .............. 58 5.15 DIAGNOSIS ......................... 58 5.16 CURRENT TREATMENT ..... 59 6 GLOBAL PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS ..... 61 6.1 OVERVIEW .......................... 61 7 GLOBAL PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY ..................................... 64 7.1 OVERVIEW .......................... 64 8 GLOBAL PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION ..................... 67 8.1 OVERVIEW .......................... 67 9 GLOBAL PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL ............................ 69 9.1 OVERVIEW .......................... 69 10 GLOBAL PREECLAMPSIA THERAPEUTICS MARKET, BY REGION ............... 72 10.1 OVERVIEW .......................... 72 10.2 NORTH AMERICA .................. 74 10.2.1 US ........................... 78 10.2.2 CANADA .................. 80 10.3 EUROPE ............................. 82 10.3.1 GERMANY ................ 86 10.3.2 UK ........................... 88 10.3.3 FRANCE ................... 90 10.3.4 NETHERLANDS ......... 92 10.3.5 ITALY ....................... 94 10.3.6 SPAIN ...................... 96 10.3.7 REST OF EUROPE ...... 98 10.4 ASIA-PACIFIC ................... 100 10.4.1 CHINA ...................... 104 10.4.2 INDIA ....................... 106 10.4.3 JAPAN ..................... 108 10.4.4 SOUTH KOREA .......... 110 10.4.5 MALAYSIA ............... 112 10.4.6 THAILAND ................ 114 10.4.7 INDONESIA .............. 116 10.4.8 REST OF APAC ......... 118 10.5 LATIN AMERICA ................... 120 10.5.1 BRAZIL ..................... 124 10.5.2 MEXICO ................... 126 10.5.3 ARGENTINA ............. 128 10.5.4 REST OF LATIN AMERICA ..................................... 130 10.6 IDDLE EAST & AFRICA ............. 132 10.6.1 GCC COUNTRIES ...... 136 10.6.2 SOUTH AFRICA ......... 138 10.6.3 REST OF MEA ........... 140 11 COMPETITIVE LANDSCAPE ................................... 143 11.1 INTRODUCTION ..................... 143 11.2 MARKET SHARE ANALYSIS, 2025 ........................................ 143 11.3 COMPETITOR DASHBOARD ....... 144 11.4 KEY DEVELOPMENTS & GROWTH STRATEGIES ............. 145 12 COMPANY PROFILES ............................................. 146 12.1 GLAXOSMITHKLINE ............... 146 12.1.1 COMPANY OVERVIEW .......................................... 146 12.1.2 FINANCIAL OVERVIEW ......................................... 147 12.1.3 PRODUCTS OFFERED ........................................... 147 12.1.4 SWOT ANALYSIS ...... 148 12.1.5 KEY STRATEGIES ...... 148 12.2 MERCK & CO. ..................... 149 12.2.1 COMPANY OVERVIEW .......................................... 149 12.2.2 FINANCIAL OVERVIEW ......................................... 150 12.2.3 PRODUCTS OFFERED ........................................... 150 12.2.4 SWOT ANALYSIS ...... 151 12.2.5 KEY STRATEGIES ...... 151 12.3 PFIZER INC. ........................ 152 12.3.1 COMPANY OVERVIEW .......................................... 152 12.3.2 FINANCIAL OVERVIEW ......................................... 153 12.3.3 PRODUCTS OFFERED ........................................... 153 12.3.4 SWOT ANALYSIS ...... 154 12.3.5 KEY STRATEGIES ...... 154 12.4 FRESENIUS KABI .................. 155 12.4.1 COMPANY OVERVIEW .......................................... 155 12.4.2 FINANCIAL OVERVIEW ......................................... 156 12.4.3 PRODUCTS OFFERED ........................................... 156 12.4.4 SWOT ANALYSIS ...... 157 12.4.5 KEY STRATEGIES ...... 157 12.5 BAXTER INTERNATIONAL .......... 158 12.5.1 COMPANY OVERVIEW .......................................... 158 12.5.2 FINANCIAL OVERVIEW ......................................... 159 12.5.3 PRODUCTS OFFERED ........................................... 160 12.5.4 SWOT ANALYSIS ...... 160 12.5.5 KEY STRATEGIES ...... 161 12.6 SUN PHARMACEUTICAL INDUSTRIES ..................................... 162 12.6.1 COMPANY OVERVIEW ......................................... 162 12.6.2 FINANCIAL OVERVIEW ......................................... 163 12.6.3 PRODUCTS OFFERED ........................................... 164 12.6.4 SWOT ANALYSIS ...... 164 12.6.5 KEY STRATEGIES ...... 165 12.7 HIKMA PHARMACEUTICALS ............................................... 166 12.7.1 COMPANY OVERVIEW .......................................... 166 12.7.2 FINANCIAL OVERVIEW ......................................... 167 12.7.3 PRODUCTS OFFERED ........................................... 168 12.7.4 SWOT ANALYSIS ...... 168 12.7.5 KEY STRATEGIES ...... 169 12.8 BAYER AG ........................... 170 12.8.1 COMPANY OVERVIEW .......................................... 170 12.8.2 FINANCIAL OVERVIEW ......................................... 171 12.8.3 PRODUCTS OFFERED ........................................... 172 12.8.4 SWOT ANALYSIS ...... 172 12.8.5 KEY STRATEGIES ...... 173 12.9 NOVARTIS AG ...................... 174 12.9.1 COMPANY OVERVIEW .......................................... 174 12.9.2 FINANCIAL OVERVIEW ......................................... 175 12.9.3 PRODUCTS OFFERED ........................................... 176 12.9.4 SWOT ANALYSIS ...... 176 12.9.5 KEY STRATEGIES ...... 177 12.10 ABBVIE INC........................ 178 12.10.1 COMPANY OVERVIEW .......................................... 178 12.10.2 FINANCIAL OVERVIEW ......................................... 179 12.10.3 PRODUCTS OFFERED ........................................... 179 12.10.4 SWOT ANALYSIS ...... 180 12.10.5 KEY STRATEGIES ...... 180 12.11 DATA CITATIONS .................. 181
圖表清單 List of Tables & Figures
LIST OF TABLES TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 35 TABLE 2 NORTH AMERICA PRICING ANALYSIS, BY PRODUCT 48 TABLE 3 EUROPE PRICING ANALYSIS, BY PRODUCT 48 TABLE 4 ASIA PACIFIC PRICING ANALYSIS, BY PRODUCT 49 TABLE 5 REST OF THE WORLD PRICING ANALYSIS, BY PRODUCT 49 TABLE 6 PRODUCT PIPELINE 56 TABLE 7 GLOBAL PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 62 TABLE 8 GLOBAL PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 65 TABLE 9 GLOBAL PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 68 TABLE 10 GLOBAL PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 70 TABLE 11 GLOBAL PREECLAMPSIA THERAPEUTICS MARKET, BY REGION, 2019-2035 (USD MILLION) 73 TABLE 12 NORTH AMERICA PREECLAMPSIA THERAPEUTICS MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 75 TABLE 13 NORTH AMERICA PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 76 TABLE 14 NORTH AMERICA PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 76 TABLE 15 NORTH AMERICA PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 76 TABLE 16 NORTH AMERICA PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 77 TABLE 17 US PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 78 TABLE 18 US PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 78 TABLE 19 US PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 78 TABLE 20 US PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 79 TABLE 21 CANADA PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 80 TABLE 22 CANADA PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 80 TABLE 23 CANADA PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 80 TABLE 24 CANADA PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 81 TABLE 25 EUROPE PREECLAMPSIA THERAPEUTICS MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 83 TABLE 26 EUROPE PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 84 TABLE 27 EUROPE PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 84 TABLE 28 EUROPE PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 85 TABLE 29 EUROPE PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 85 TABLE 30 GERMANY PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 86 TABLE 31 GERMANY PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 86 TABLE 32 GERMANY PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 86 TABLE 33 GERMANY PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 87 TABLE 34 UK PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 88 TABLE 35 UK PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 88 TABLE 36 UK PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 88 TABLE 37 UK PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 89 TABLE 38 FRANCE PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 90 TABLE 39 FRANCE PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 90 TABLE 40 FRANCE PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 90 TABLE 41 FRANCE PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 91 TABLE 42 NETHERLANDS PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 92 TABLE 43 NETHERLANDS PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 92 TABLE 44 NETHERLANDS PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 92 TABLE 45 NETHERLANDS PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 93 TABLE 46 ITALY PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 94 TABLE 47 ITALY PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 94 TABLE 48 ITALY PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 94 TABLE 49 ITALY PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 95 TABLE 50 SPAIN PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 96 TABLE 51 SPAIN PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 96 TABLE 52 SPAIN PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 96 TABLE 53 SPAIN PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 97 TABLE 54 REST OF EUROPE PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 98 TABLE 55 REST OF EUROPE PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 98 TABLE 56 REST OF EUROPE PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 98 TABLE 57 REST OF EUROPE PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 99 TABLE 58 ASIA-PACIFIC PREECLAMPSIA THERAPEUTICS MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 101 TABLE 59 ASIA-PACIFIC PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 102 TABLE 60 ASIA-PACIFIC PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 102 TABLE 61 ASIA-PACIFIC PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 103 TABLE 62 ASIA-PACIFIC PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 103 TABLE 63 CHINA PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 104 TABLE 64 CHINA PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 104 TABLE 65 CHINA PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 104 TABLE 66 CHINA PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 105 TABLE 67 INDIA PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 106 TABLE 68 INDIA PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 106 TABLE 69 INDIA PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 106 TABLE 70 INDIA PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 107 TABLE 71 JAPAN PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 108 TABLE 72 JAPAN PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 108 TABLE 73 JAPAN PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 108 TABLE 74 JAPAN PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 109 TABLE 75 SOUTH KOREA PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 110 TABLE 76 SOUTH KOREA PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 110 TABLE 77 SOUTH KOREA PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 110 TABLE 78 SOUTH KOREA PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 111 TABLE 79 MALAYSIA PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 112 TABLE 80 MALAYSIA PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 112 TABLE 81 MALAYSIA PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 112 TABLE 82 MALAYSIA PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 113 TABLE 83 THAILAND PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 114 TABLE 84 THAILAND PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 114 TABLE 85 THAILAND PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 114 TABLE 86 THAILAND PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 115 TABLE 87 INDONESIA PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 116 TABLE 88 INDONESIA PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 116 TABLE 89 INDONESIA PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 116 TABLE 90 INDONESIA PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 117 TABLE 91 REST OF APAC PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 118 TABLE 92 REST OF APAC PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 118 TABLE 93 REST OF APAC PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 118 TABLE 94 REST OF APAC PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 119 TABLE 95 LATIN AMERICA PREECLAMPSIA THERAPEUTICS MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 121 TABLE 96 LATIN AMERICA PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 122 TABLE 97 LATIN AMERICA PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 122 TABLE 98 LATIN AMERICA PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 122 TABLE 99 LATIN AMERICA PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 123 TABLE 100 BRAZIL PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 124 TABLE 101 BRAZIL PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 124 TABLE 102 BRAZIL PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 124 TABLE 103 BRAZIL PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 125 TABLE 104 MEXICO PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 126 TABLE 105 MEXICO PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 126 TABLE 106 MEXICO PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 126 TABLE 107 MEXICO PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 127 TABLE 108 ARGENTINA PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 128 TABLE 109 ARGENTINA PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 128 TABLE 110 ARGENTINA PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 128 TABLE 111 ARGENTINA PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 129 TABLE 112 REST OF LATIN AMERICA PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 130 TABLE 113 REST OF LATIN AMERICA PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 130 TABLE 114 REST OF LATIN AMERICA PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 130 TABLE 115 REST OF LATIN AMERICA PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 131 TABLE 116 MIDDLE EAST & AFRICA PREECLAMPSIA THERAPEUTICS MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 133 TABLE 117 MIDDLE EAST & AFRICA PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 134 TABLE 118 MIDDLE EAST & AFRICA PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 134 TABLE 119 MIDDLE EAST & AFRICA PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 134 TABLE 120 MIDDLE EAST & AFRICA PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 135 TABLE 121 GCC COUNTRIES PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 136 TABLE 122 GCC COUNTRIES PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 136 TABLE 123 GCC COUNTRIES PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 136 TABLE 124 GCC COUNTRIES PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 137 TABLE 125 SOUTH AFRICA PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 138 TABLE 126 SOUTH AFRICA PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 138 TABLE 127 SOUTH AFRICA PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 138 TABLE 128 SOUTH AFRICA PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 139 TABLE 129 REST OF MEA PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 140 TABLE 130 REST OF MEA PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 140 TABLE 131 REST OF MEA PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 140 TABLE 132 REST OF MEA PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 141 TABLE 133 KEY DEVELOPMENT 145 TABLE 134 GLAXOSMITHKLINE: PRODUCTS OFFERED 147 TABLE 135 MERCK & CO : PRODUCT OFFERED 150 TABLE 136 PFIZER INC. : PRODUCT OFFERED 153 TABLE 137 FRESENIUS KABI . : PRODUCT OFFERED 156 TABLE 138 BAXTER INTERNATIONAL: PRODUCTS OFFERED 160 TABLE 139 SUN PHARMACEUTICAL INDUSTRIES .: PRODUCT OFFERED 164 TABLE 140 HIKMA PHARMACEUTICALS: PRODUCT OFFERED 168 TABLE 141 BAYERS AG: PRODUCT OFFERED 172 TABLE 142 NOVARTIS AG: PRODUCT OFFERED 176 TABLE 143 ABBVIE INC: PRODUCT OFFERED 179 LIST OF FIGURES FIGURE 1 GLOBAL PREECLAMPSIA THERAPEUTICS MARKET: STRUCTURE 21 FIGURE 2 GLOBAL PREECLAMPSIA THERAPEUTICS MARKET: MARKET GROWTH AFFECTING FACTOR ANALYSIS (2019-2035) 38 FIGURE 3 GLOBAL PREECLAMPSIA THERAPEUTICS MARKET DRIVER: IMPACT ANALYSIS 41 FIGURE 4 GLOBAL PREECLAMPSIA THERAPEUTICS MARKET RESTRAINT: IMPACT ANALYSIS 44 FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL PREECLAMPSIA THERAPEUTICS MARKET 54 FIGURE 6 GLOBAL PREECLAMPSIA THERAPEUTICS MARKET, DRUG CLASS SEGMENT ATTRACTIVENESS, 2025 & 2035 (USD MILLION) 61 FIGURE 7 GLOBAL PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2025 & 2035 (USD MILLION) 62 FIGURE 8 GLOBAL PREECLAMPSIA THERAPEUTICS MARKET SHARE (%), BY DRUG CLASS, 2025 63 FIGURE 9 GLOBAL PREECLAMPSIA THERAPEUTICS MARKET, DISEASE SEVERITY SEGMENT ATTRACTIVENESS, 2025 & 2035 (USD MILLION) 64 FIGURE 10 GLOBAL PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2025 & 2035 (USD MILLION) 65 FIGURE 11 GLOBAL PREECLAMPSIA THERAPEUTICS MARKET SHARE (%), BY DISEASE SEVERITY, 2025 66 FIGURE 12 GLOBAL PREECLAMPSIA THERAPEUTICS MARKET, ROUTE OF ADMINISTRATION SEGMENT ATTRACTIVENESS, 2025 & 2035 (USD MILLION) 67 FIGURE 13 GLOBAL PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2025 & 2035 (USD MILLION) 67 FIGURE 14 GLOBAL PREECLAMPSIA THERAPEUTICS MARKET SHARE (%), BY ROUTE OF ADMINISTRATION, 2025 68 FIGURE 15 GLOBAL PREECLAMPSIA THERAPEUTICS MARKET, DISTRIBUTION CHANNEL SEGMENT ATTRACTIVENESS, 2025 & 2035 (USD MILLION) 69 FIGURE 16 GLOBAL PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2025 & 2035 (USD MILLION) 70 FIGURE 17 GLOBAL PREECLAMPSIA THERAPEUTICS MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2025 71 FIGURE 18 GLOBAL PREECLAMPSIA THERAPEUTICS MARKET, BY REGION, 2025 & 2035 (USD MILLION) 72 FIGURE 19 GLOBAL PREECLAMPSIA THERAPEUTICS MARKET SHARE (%), BY REGION, 2025 73 FIGURE 20 NORTH AMERICA MARKET ANALYSIS: PREECLAMPSIA THERAPEUTICS MARKET, 2019-2035 (USD MILLION) 74 FIGURE 21 NORTH AMERICA PREECLAMPSIA THERAPEUTICS MARKET, BY COUNTRY, 2025 & 2035 (USD MILLION) 75 FIGURE 22 NORTH AMERICA PREECLAMPSIA THERAPEUTICS MARKET SHARE (%), BY COUNTRY, 2025 75 FIGURE 23 EUROPE MARKET ANALYSIS: PREECLAMPSIA THERAPEUTICS MARKET, 2019-2035 (USD MILLION) 82 FIGURE 24 EUROPE PREECLAMPSIA THERAPEUTICS MARKET, BY COUNTRY, 2025 & 2035 (USD MILLION) 83 FIGURE 25 EUROPE PREECLAMPSIA THERAPEUTICS MARKET SHARE (%), BY COUNTRY, 2025 84 FIGURE 26 ASIA-PACIFIC MARKET ANALYSIS: PREECLAMPSIA THERAPEUTICS MARKET, 2019-2035 (USD MILLION) 100 FIGURE 27 ASIA-PACIFIC PREECLAMPSIA THERAPEUTICS MARKET, BY COUNTRY, 2025 & 2035 (USD MILLION) 101 FIGURE 28 ASIA-PACIFIC PREECLAMPSIA THERAPEUTICS MARKET SHARE (%), BY COUNTRY, 2025 102 FIGURE 29 LATIN AMERICA MARKET ANALYSIS: PREECLAMPSIA THERAPEUTICS MARKET, 2019-2035 (USD MILLION) 120 FIGURE 30 LATIN AMERICA PREECLAMPSIA THERAPEUTICS MARKET, BY COUNTRY, 2025 & 2035 (USD MILLION) 121 FIGURE 31 LATIN AMERICA PREECLAMPSIA THERAPEUTICS MARKET SHARE (%), BY COUNTRY, 2025 121 FIGURE 32 MIDDLE EAST & AFRICA MARKET ANALYSIS: PREECLAMPSIA THERAPEUTICS MARKET, 2019-2035 (USD MILLION) 132 FIGURE 33 MIDDLE EAST & AFRICA PREECLAMPSIA THERAPEUTICS MARKET, BY COUNTRY, 2025 & 2035 (USD MILLION) 132 FIGURE 34 MIDDLE EAST & AFRICA PREECLAMPSIA THERAPEUTICS MARKET SHARE (%), BY COUNTRY, 2025 133 FIGURE 35 GLOBAL PREECLAMPSIA THERAPEUTICS MARKET: COMPETITIVE ANALSIS, 2025 143 FIGURE 36 COMPETITOR DASHBOARD: GLOBAL PREECLAMPSIA THERAPEUTICS MARKET 144 FIGURE 37 GLAXOSMITHKLINE: SWOT ANALYSIS 148 FIGURE 38 MERCK & CO: SWOT ANALYSIS 151 FIGURE 39 PFIZER INC: SWOT ANALYSIS 154 FIGURE 40 FRESENIUS KABI: SWOT ANALYSIS 157 FIGURE 41 BAXTER INTERNATIONAL: SWOT ANALYSIS 160 FIGURE 42 SUN PHARMACEUTICAL INDUSTRIES: SWOT ANALYSIS 164 FIGURE 43 HIKMA PHARMACEUTICALS: SWOT ANALYSIS 168 FIGURE 44 BAYERS AG: SWOT ANALYSIS 172 FIGURE 45 NOVARTIS AG: SWOT ANALYSIS 176 FIGURE 46 ABBVIE INC: SWOT ANALYSIS 180

提及公司

GlaxoSmithKlineMerck & Co.Pfizer Inc.Bayer AGFresenius KabiAbbVie Inc.Sun PharmaceuticalIndustriesHikmaPharmaceuticalsBaxter InternationalNovartis AG

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們